Sign inJoin waitlistJoin the waitlist

Mehmet Akce

Professor · University of Alabama Hospital

Credentials: · · · · · · ·

History

University of Alabama Hospital
Present

Hematology and Medical Oncology
Baylor College of Medicine
2014–2017
Internal Medicine
Trinity Health Ann Arbor Hospital
2011–2014
MARMARA UNIV,ISTANBUL
2005–2009

Research

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
Review · British Journal of Cancer · 2019 · 320 citations
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy
Cancer · 2019 · 142 citations
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
BMC Cancer · 2019 · 113 citations

Bassel El-Rayes
63 papers
Olatunji Alese
38 papers
Christina Wu
37 papers
Walid Shaib
37 papers
KZ
Katerina Zakka
20 papers · 10 as a resident
Mehmet Bilen
9 papers
Midhun Malla
8 papers
Shishir Maithel
7 papers
Taofeek Owonikoko
7 papers
Bradley Carthon
6 papers
Conor Steuer
6 papers
Darryl Outlaw
6 papers

Grants

Preoperative Immunotherapy in Hepatocellular Carcinoma
National Cancer Institute · R21
PI · $393.3K · Emory University
2023–2027

Clinical trials

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Principal investigator · Not yet recruiting · Phase 2
Mehmet Akce
2026–2028
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Principal investigator · Recruiting · Phase 2
Mehmet Akce
2026–2028
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
Principal investigator · Recruiting · Phase 1, Phase 2
University of Alabama at Birmingham
2025–2028
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
Principal investigator · Recruiting · Phase 1
ProDa BioTech, LLC
2023–2028